| Literature DB >> 27930349 |
Roel J R Snijder1, Justin G L M Luermans2, Albert H de Heij3, Vincent Thijs4,5, Wouter J Schonewille6, Alexander Van De Bruaene7, Martin J Swaans8, Werner I H L Budts9, Martijn C Post8.
Abstract
BACKGROUND: A patent foramen ovale (PFO) with atrial septal aneurysm (ASA) has been identified as a risk factor for cryptogenic stroke. Patients with migraine with aura (MA) appear to be at risk for silent brain infarction, which might be related to the presence of a PFO. However, the association between MA and PFO with ASA has never been reported. We examined this association in a large observational study. METHODS ANDEntities:
Keywords: atrial septal aneurysm; cerebrovascular disorders; echocardiography; heart septal defect; migraine; patent foramen ovale
Mesh:
Year: 2016 PMID: 27930349 PMCID: PMC5210450 DOI: 10.1161/JAHA.116.003771
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Flowchart of patient inclusion. ASD indicates atrial septal defect; cTEE, transesophageal echocardiography with agitated saline; OPD, outpatient department; TEE, transesophageal echocardiography.
Patient Characteristics, Interatrial Septal Anatomy and Occurrence of Migraine (MA and MA−)
| Patient Population (n=889) | |
|---|---|
| Patient characteristics | |
| Age (y) ±SD | 56.4±14.3 |
| Women, n (%) | 371 (41.7) |
| Mean BMI (kg/m2) ±SD | 26.2±4.5 |
| History | |
| Stroke or TIA, % | 34.7 |
| CAD, % | 14.2 |
| Diabetes mellitus, % | 7.5 |
| Hypertension, % | 34.0 |
| Hypercholesterolemia, % | 34.3 |
| Smoking, % | 31.4 |
| Atrial fibrillation, % | 32.8 |
| Medication | |
| Aspirin, % | 32.8 |
| Warfarin, % | 31.6 |
| β‐Blocker, % | 42.0 |
| Indication for TEE | |
| Suspicion of endocarditis, % | 3.1 |
| Evaluation of valve abnormalities/prosthesis, % | 18.9 |
| Evaluation of cardioembolic source, % | 45.1 |
| Evaluation of atrial thrombi pre‐PVI/ECV, % | 20.2 |
| PFO on cTTE, % | 8.5 |
| Other, % | 4.2 |
| Interatrial septal anatomy | |
| No PFO, no ASA, n (%) | 659 (74.1) |
| Isolated PFO, n (%) | 145 (16.3) |
| Isolated ASA, n (%) | 24 (2.7) |
| PFO with ASA, n (%) | 61 (6.9) |
| Migraine | |
| Migraine, n (%) | 168 (18.9) |
| Migraine without aura, n (%) | 96 (10.8) |
| Migraine with aura, n (%) | 72 (8.1) |
ASA indicates atrial septal aneurysm; BMI, body mass index; CAD, coronary artery disease; cTTE, agitated saline transthoracic echocardiography; ECV, electrical cardioversion; n, number; PFO, patent foramen ovale; PVI, pulmonary vein isolation; SD, standard deviation; TEE, transesophageal echocardiography; TIA, transient ischemic attack.
Factors Associated With MA and MA−, Univariate Analysis
| No Migraine | MA | MA− | OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| |
|---|---|---|---|---|---|---|---|---|---|
| Patient characteristics | MA vs no migraine | MA− vs no migraine | MA vs MA− | ||||||
| Total | 721 | 72 | 96 | — | — | — | — | ||
| Age (y) ±SD | 58.5±13.6 | 44.4±14.1 | 49.6±13.2 | 0.93 (0.92‐0.95) | <0.001 | 0.96 (0.94‐0.97) | <0.001 | 0.97 (0.95‐1.00) | 0.02 |
| Women, n (%) | 269 (37.3) | 48 (66.7) | 54 (56.3) | 3.36 (2.01‐5.61) | <0.001 | 2.16 (1.41‐3.32) | <0.001 | 1.56 (0.83‐2.93) | 0.17 |
| BMI (kg/m2) ±SD | 26.4±4.2 | 26.7±6.7 | 24.7±4.3 | 1.02 (0.94‐1.10) | 0.71 | 0.90 (0.82‐0.97) | 0.01 | 1.07 (0.98‐1.17) | 0.12 |
| History | |||||||||
| Stroke or TIA, % | 33.8 | 40.3 | 37.2 | 1.32 (0.79‐2.21) | 0.87 | 1.16 (0.73‐1.85) | 0.53 | 1.14 (0.59‐2.19) | 0.70 |
| CAD, % | 16.1 | 3.0 | 8.2 | 0.16 (0.04‐0.67) | 0.01 | 0.47 (0.21‐1.04) | 0.06 | 0.34 (0.07‐1.71) | 0.19 |
| Diabetes mellitus, % | 7.7 | 4.5 | 8.1 | 0.56 (0.17‐1.85) | 0.34 | 1.06 (0.47‐2.42) | 0.88 | 0.53 (0.13‐2.13) | 0.37 |
| Hypertension, % | 37.3 | 16.4 | 22.1 | 0.33 (0.17‐0.64) | 0.01 | 0.48 (0.28‐0.81) | 0.006 | 0.69 (0.30‐1.58) | 0.42 |
| Hypercholesterolemia, % | 37.0 | 19.4 | 25.6 | 0.41 (0.22‐0.77) | 0.005 | 0.59 (0.35‐0.98) | 0.04 | 0.70 (0.32‐1.52) | 0.44 |
| Smoking, % | 29.6 | 29.4 | 42.6 | 0.99 (0.45‐2.18) | 0.98 | 1.76 (0.93‐3.34) | 0.08 | 0.56 (0.22‐1.44) | 0.25 |
| AF, % | 37.2 | 13.4 | 14.0 | 0.26 (0.13‐0.54) | <0.001 | 0.27 (0.15‐0.51) | <0.001 | 0.96 (0.38‐2.43) | 1.00 |
| Medication | |||||||||
| Aspirin, % | 32.9 | 38.1 | 28.6 | 1.26 (0.74‐2.14) | 0.40 | 0.82 (0.50‐1.35) | 0.43 | 1.54 (0.77‐3.08) | 0.29 |
| Warfarin, % | 34.7 | 10.9 | 22.6 | 0.23 (0.10‐0.51) | <0.001 | 0.55 (0.32‐0.94) | 0.03 | 0.42 (0.17‐1.07) | 0.08 |
| β‐Blocker, % | 44.3 | 35.9 | 28.6 | 0.71 (0.41‐1.20) | 0.20 | 0.50 (0.31‐0.83) | 0.007 | 1.40 (0.70‐2.81) | 0.38 |
| Interatrial septal anatomy | |||||||||
| No PFO, no ASA, n (%) | 542 (75.2) | 43 (59.7) | 74 (77.1) | Reference | — | Reference | — | Reference | — |
| Isolated PFO, n (%) | 118 (16.4) | 14 (19.4) | 13 (13.5) | 1.50 (0.79‐2.82) | 0.21 | 0.81 (0.43‐1.50) | 0.50 | 1.85 (0.80‐4.31) | 0.15 |
| Isolated ASA, n (%) | 17 (2.4) | 2 (2.8) | 5 (5.2) | 1.48 (0.33‐6.63) | 0.61 | 2.15 (0.77‐6.01) | 0.14 | 0.69 (0.13‐3.70) | 0.66 |
| PFO with ASA, n (%) | 44 (6.1) | 13 (18.1) | 4 (4.2) | 3.72 (1.86‐7.44) | <0.001 | 0.67 (0.23‐1.91) | 0.45 | 5.59 (1.72‐18.2) | 0.004 |
AF indicates atrial fibrillation; ASA, atrial septal aneurysm; BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; MA, migraine with aura; MA−, migraine without aura; n, number; OR, odds ratio; PFO, patent foramen ovale; SD, standard deviation; TIA, transient ischemic attack.
PFO Grade in Patients With M−, MA− and MA
| Grade 0, % | Grade 1, % | Grade 2, % | Grade 3, % | |
|---|---|---|---|---|
| M− | 80.6 | 6.8 | 7.0 | 5.6 |
| MA− | 88.6 | 5.7 | 5.7 | 0.0 |
| MA | 60.0 | 16.0 | 12.0 | 12.0 |
| Isolated PFO | — | 44.4 | 35.2 | 20.4 |
| PFO with ASA | — | 20.7 | 37.9 | 41.4 |
PFO grade, maximum number of microbubbles counted in the left ventricle in 1 still frame: grade 0 (no microbubbles), grade 1 (1‐29 microbubbles), grade 2 (30‐100 microbubbles), and grade 3 (>100 microbubbles). ASA indicates atrial septal aneurysm; M−, no migraine; MA, migraine with aura; MA−, migraine without aura; PFO, patent foramen ovale.
Characteristics of Headache Attacks in Relation to Interatrial Septal Anatomy in Patients With MA (n=72)
| No PFO, No ASA n=43 | Isolated PFO n=14 | Isolated ASA n=2 | PFO With ASA n=13 |
| |
|---|---|---|---|---|---|
| Median duration, h (IQ1‐IQ3) | 4 (1‐24) | 1.5 (0.8‐4) | 36 (0.25‐72) | 24 (1.4‐24) | 0.51 |
| Median severity score, scale 0 to 10 (IQ1‐IQ3) | 7 (5‐8) | 7.5 (6‐8) | 6.5 (5‐8) | 7 (6‐8) | 0.62 |
| Frequency of migraine, n of patients | 0.37 | ||||
| ≥Once a month | 21 | 9 | 0 | 7 | |
| ≥Once a week | 22 | 5 | 2 | 6 |
Kruskal‐Wallis tests were performed to compare headache characteristics between groups. ASA indicates atrial septal aneurysm; IQ, interquartile; MA, migraine with aura; n, number; PFO, patent foramen ovale.